Montazeri Mahbobeh, Daryani Ahmad, Ebrahimzadeh Mohammadali, Ahmadpour Ehsan, Sharif Mehdi, Sarvi Shahabeddin
Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran ; Department of Parasitology and Mycology, Sari Medical School, Mazandaran University of Medical Sciences, Sari, IR Iran.
Pharmaceutical Sciences Research Center, School of Pharmacy, Mazandaran University of Medical Sciences Sari, IR Iran.
Jundishapur J Microbiol. 2015 Sep 7;8(9):e22572. doi: 10.5812/jjm.22572. eCollection 2015 Sep.
Toxoplasmosis is a public health problem worldwide. This complication principally affects immunodeficient patients and pregnant women. Toxoplasma gondii is an opportunistic parasite, causing severe illness among and death of high-risk individuals and treatment is becoming increasingly difficult owing to side effects and low efficacies of drugs.
In this study, we investigated the anti-Toxoplasma gondii efficacy of propranolol in vivo.
This study was performed in two separate pre-treatment and post-treatment groups. In each group, 18 female Balb/c mice in six subgroups (n = 3) were used to assess the anti-Toxoplasma effect of propranolol at 2 and 3 mg/kg/day, pyrimethamine at 50 mg/kg/day, propranolol at 2 and 3 mg/kg/day plus pyrimethamine, and phosphate-buffered saline (PBS; as negative control). Treatment was performed 4, 24, and 48 hours before and after an intraperitoneal challenge of 1 × 10(3) tachyzoites of the virulent RH strain of T. gondii, in pre-treatment and post-treatment groups. Mice peritoneal exudates were collected on the seventh day after the challenge and parasite numbers were recorded as percent of growth inhibition and survival rate.
In the pre-treatment group, results showed that propranolol at 2 and 3 mg/kg combined with pyrimethamine was more effective in inhibiting growth of tachyzoites (86% and 98%, respectively) when compared with propranolol at 2 and 3 mg/kg (37% and 39%, respectively) and pyrimethamine (41%) alone. In the post-treatment group, all combined treatments significantly reduced parasite load. The growth inhibition of tachyzoites in mice receiving propranolol (2 and 3 mg/kg) was 75% and 51%, with the mean tachyzoites count being 1526 ± 171.4 and 2948 ± 1452.8, respectively, compared with pyrimethamine treatment outcome, which represents 99.9% growth inhibition.
Our results demonstrated the promising prophylactic and therapeutic effects of propranolol against T. gondii infection. Propranolol also increases the efficacy of pyrimethamine in combination therapies.
弓形虫病是一个全球性的公共卫生问题。这种并发症主要影响免疫功能低下的患者和孕妇。刚地弓形虫是一种机会性寄生虫,会导致高危个体患病和死亡,并且由于药物的副作用和低效性,治疗变得越来越困难。
在本研究中,我们调查了普萘洛尔在体内抗刚地弓形虫的疗效。
本研究在两个独立的预处理组和治疗后组中进行。每组中,将18只雌性Balb/c小鼠分为六个亚组(n = 3),以评估2和3mg/kg/天的普萘洛尔、50mg/kg/天的乙胺嘧啶、2和3mg/kg/天的普萘洛尔加乙胺嘧啶以及磷酸盐缓冲盐水(PBS;作为阴性对照)的抗弓形虫效果。在预处理组和治疗后组中,在腹腔注射1×10³ 刚地弓形虫强毒株RH株速殖子之前和之后的4、24和48小时进行治疗。在攻击后第七天收集小鼠腹腔渗出液,并将寄生虫数量记录为生长抑制百分比和存活率。
在预处理组中,结果表明,与2和3mg/kg的普萘洛尔(分别为37%和39%)和单独的乙胺嘧啶(41%)相比,2和3mg/kg的普萘洛尔与乙胺嘧啶联合使用在抑制速殖子生长方面更有效(分别为86%和98%)。在治疗后组中,所有联合治疗均显著降低了寄生虫载量。接受普萘洛尔(2和3mg/kg)的小鼠中速殖子的生长抑制率分别为75%和51%,平均速殖子计数分别为1526±171.4和2948±1452.8,而乙胺嘧啶治疗的结果显示生长抑制率为99.9%。
我们的结果证明了普萘洛尔对弓形虫感染具有有前景的预防和治疗作用。普萘洛尔在联合治疗中还提高了乙胺嘧啶的疗效。